Navigation Links
Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
Date:3/28/2011

Option Offer Condition Period means the period beginning on the Announcement Date and ending at the end of the Listed Option Offer Period.

Listed Option Offer Period means the period during which the Listed Option Offer remains open.

Offer means the Listed Option Offer or Share Offer, as the context requires.

Offer Period means the Listed Option Offer Period or the Share Offer Period, as the context requires.

Regulatory Authority means any governmental, semi-governmental, administrative, statutory or judicial entity, authority or agency, whether in Australia or elsewhere, including any self-regulatory organisation established under statute or any stock exchange but excluding the Takeovers Panel, ASIC and any court that hears or determines proceedings under section 657G of the Corporations Act or proceedings commenced under the Corporations Act by a person specified in section 659B(1) in relation to the Share Offer or Listed Option Offer.

Share Offer means the offer by Cephalon CXS to acquire ChemGenex Shares on the Share Offer Conditions.

Share Offer Conditions means the terms and conditions of the Share Offer to be set out in the Bidder's Statement.

Share Offer Condition Period means the period beginning on the Announcement Date and ending at the end of the Share Offer Period.

Share Offer Period means the period during which the Share Offer remains open.

subsidiary has the meaning given to it in the Corporations Act.

Target's Statement means the statement to be made by ChemGenex in response to the Bidder's Statement, as required by the Corporations Act.

Unlisted Option Cancellation Letters means the letter agreements entered into on or about the Announcement Date between ChemGenex and certain employees and directors of members of the ChemGenex Group relating to the cancellation of unlisted options over unissue
'/>"/>

SOURCE Cephalon, Inc.; ChemGenex Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Cephalon Announces Definitive Agreement to Acquire Gemin X
3. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
4. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
5. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
6. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
7. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
8. Cephalon to Webcast Investor Day
9. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
10. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
11. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 1, 2014   Intarcia Therapeutics, Inc. today ... phase 3 clinical trials for ITCA 650 (exenatide, delivered ... osmotic mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, ... and safety of ITCA 650 in patients with type ... to be significantly superior to placebo for both 40 ...
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3NeuroCall Awarded Joint Commission Accreditation 2
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:10/1/2014)... from the University of Adelaide have developed a model ... a good outcome from treatment - from their very ... a range of factors, including clinical symptoms, cognitive abilities, ... the patient,s blood. , Speaking in the lead up ... Head of Psychiatry , Professor Bernhard Baune ...
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Beverly Hills, California (PRWEB) October 01, 2014 ... relationship expert, Dr. Kathleen Mojas is celebrating 20 years ... she has assisted hundreds of people to achieve greater ... released an important list of warning signs and suggestions ... relationship. , Dr. Mojas explains: “Believe it or ...
Breaking Medicine News(10 mins):Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... eye mainly during the surgical treatment of retinal hemorrhages or ... the detached retina to the wall of the eye. There ... during airplane travel, at high altitudes, or under nitrous oxide ... risk remains present for weeks after the surgical procedure. , ...
... ATLANTA, Feb. 25 CIBER, Inc. ... and implemented a service-oriented,architecture (SOA)-based software application ... for Disease Control and Prevention (CDC). CDCAS,reliably, ... and public,health organizations of disease outbreaks, bioterrorism ...
... small-diameter implants expanded more than 30% in 2007, ... according to Millennium Research Group, ... shows that small-diameter (less than or equal to 3.0 mm),dental ... implants are growing at a faster rate than those of ...
... Park have discovered that Normal Human Bronchial Epithelial (NHBE) ... the high end of plasma zinc attainable by oral ... arrest and DNA damage-induced gene (Gadd45) mRNA and protein ... research, published in the March 08 issue of the ...
... February 24, 2008: With a deep understanding of healthcare ... a global medical publisher, Elsevier is broadening its efforts ... (CDS) tools that help providers make optimal decisions at ... acquired CPM Resource Center, a provider of interactive nursing ...
... who examined blood test records in a survey of over ... found thousands of cases of probable undiagnosed diabetes. This could ... in UK. , The research is published in the ... was led by Dr Tim Holt of the University of ...
Cached Medicine News:Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 2Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 3Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 4Health News:Small-Diameter Dental Implants Increasingly Popular In the US 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 3Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 2Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 3Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 4Health News:GP's databases could identify tens of thousands with undiagnosed diabetes in UK 2
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
Bipolar Atrial "J" Lead...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: